Data governance is on the rise, but still faces barriers

Dimensional Insight, developers of business intelligence solutions, has released a survey on current data governance within hospitals in America. The survey includes responses from CIOs and CMIOs in an overview of current data governance initiatives with an eye toward the future of implementation.

Implementation of data governance practices within hospitals has been slow. This survey analyzed current data governance practices to provide insight into how hospitals can overcome barriers to improve effectiveness.

Findings included:

  • 44 percent of respondents had implemented an organization-wide data governance system; the remaining 56 percent had incomplete or non-existent governance practices.
  • 49 percent of respondents had a plan to implement data governance within the next year; 29 percent planned on implementing within three years.
  • 68 percent stated “improving trust” as the main reason for data governance implementation, followed by improving care quality at 60 percent and improving regulatory compliance at 45 percent.
  • 70 percent of respondents stated a lack of resources as the main barrier to data governance adoption, followed by variance in leadership buy-in at 50 percent and discrepancy in defining data measurements at 49 percent.

“As the amount of data continues to grow, and as healthcare organizations recognize the need to make better use of data, having an effective data governance strategy in place is more important than ever,” said Fred Powers, co-founder and CEO of Dimensional Insight. “However, as indicated in our survey, there is still a need to make the governance process easier for everyone involved so that data is consistent, well-documented and trustworthy. The time is now to make that a reality for healthcare.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.